Kura Oncology, Inc.
KURA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001422143
In the last 90 days, Kura Oncology, Inc. insiders filed 2 open-market purchases and 8 sales; 221 institutions reported holding it in 13F filings for Q2 2026, worth $953.1M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Kura Oncology, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 200
- +19 vs. Q2 2025
- Shares held
- 83.9M
- +1.83M (+2.2%) vs. Q2 2025
- Total value
- $742.6M
- +$269.0M (+56.8%) vs. Q2 2025
- New holders
- 43
- 77 more added
- Sold out
- 24
- 50 more reduced
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KURA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 221 | $953.1M |
| Q1 2026 | 222 | $686.5M |
| Q4 2025 | 215 | $888.2M |
| Q3 2025 | 200 | $742.6M |
| Q2 2025 | 182 | $473.6M |
| Q1 2025 | 183 | $530.9M |
| Q4 2024 | 185 | $686.3M |
| Q3 2024 | 179 | $1.61B |
| Q2 2024 | 174 | $1.66B |
| Q1 2024 | 165 | $1.72B |
| Q4 2023 | 141 | $1.13B |
| Q3 2023 | 133 | $686.9M |
| Q2 2023 | 148 | $795.1M |
| Q1 2023 | 141 | $885.3M |
| Q4 2022 | 142 | $870.3M |
| Q3 2022 | 148 | $977.5M |
| Q2 2022 | 148 | $1.26B |
| Q1 2022 | 152 | $1.06B |
| Q4 2021 | 151 | $897.8M |
| Q3 2021 | 152 | $1.25B |
| Q2 2021 | 171 | $1.41B |
| Q1 2021 | 171 | $1.94B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Kura Oncology, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Foresite Capital Management IV, LLC | 0 | $0 | 0.00% | −816,882−100.0% | Sold out |
| TCG Crossover Management, LLC | 0 | $0 | 0.00% | −735,184−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −414,322−100.0% | Sold out |
| Apis Capital Advisors, LLC | 0 | $0 | 0.00% | −180,000−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −140,713−100.0% | Sold out |
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −121,884−100.0% | Sold out |
| Magnetar Financial LLC | 0 | $0 | 0.00% | −76,329−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −64,705−100.0% | Sold out |
| Axq Capital, LP | 0 | $0 | 0.00% | −45,472−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −31,546−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −30,766−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −30,025−100.0% | Sold out |
| Amundi | 0 | $0 | 0.00% | −26,950−100.0% | Sold out |
| Stonepine Capital Management, LLC | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Bridgefront Capital, LLC | 0 | $0 | 0.00% | −18,708−100.0% | Sold out |
| CI Private Wealth, LLC | 0 | $0 | 0.00% | −13,838−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −11,873−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −11,283−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −314−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −291−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −268−100.0% | Sold out |
| Bare Financial Services, Inc | 0 | $0 | 0.00% | −88−100.0% | Sold out |
| Kilter Group LLC | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| CIBC Private Wealth Group, LLC | 0 | $0 | 0.00% | −9−100.0% | Sold out |
| E Fund Management Co., Ltd. | – | – | – | – | Not filed |